US nod for injectable bipolar drug a welcome boost for Lundbeck
Danish CNS specialist Lundbeck (LUND: CO) and Japan’s Otsuka Pharmaceutical (TYO: 4768) have announced that Abilify Maintena (aripiprazole) for extended-release injectable suspension has been approved by the US Food and Drug Administration (FDA) for the maintenance monotherapy treatment of bipolar I disorder in adults.
It is the first FDA-approved, once-monthly, long-acting injectable for this recurrent chronic mental illness, having been created by Otsuka and co-developed and co-commercialized with Lundbeck. It is also used for schizophrenia.
Joseph Calabrese, director of the Mood Disorders Program at University Hospitals Cleveland Medical Center, USA, said: “Abilify Maintena provides healthcare professionals (HCPs) a new treatment option for their patients who have established tolerability with oral aripiprazole.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze